Cellectar Biosciences INC NEW
CLRB Real Time Price USDRecent trades of CLRB by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CLRB's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
CLRB Revenue by Segment or Geography
New patents grants
-
Patent Title: Luminescent phospholipid analogs for the identification and isolation of circulating tumor cells Oct. 11, 2022
-
Patent Title: Phospholipid ether analogs as cancer-targeting drug vehicles Sep. 13, 2022
-
Patent Title: Phospholipid ether analogs as cancer-targeting drug vehicles Mar. 27, 2018
-
Patent Title: Fluorescent phospholipid ether compounds, compositions, and methods of use Apr. 11, 2017
-
Patent Title: Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof Feb. 28, 2017
-
Patent Title: Phospholipid analogs as diapeutic agents and methods thereof Jan. 24, 2017
-
Patent Title: Phospholipid ether analogs as cancer-targeting drug vehicles Nov. 01, 2016
-
Patent Title: Phospholipid ether analogs as cancer-targeting drug vehicles May. 24, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to CLRB
Recent picks made for CLRB stock on CNBC
ETFs with the largest estimated holdings in CLRB
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $CLRB stock a Buy, Sell, or Hold?
- What is the price target for $CLRB stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $CLRB stock?
- Who owns the most shares of $CLRB stock?
- What funds own $CLRB stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CLRB Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.